Edwards Lifesciences Corp (EW) 101.87 $EW
SmarTrend Watching for Potential Pullback in Shares of Edwards Lifesciences After 1.53% Gain
Comtex SmarTrend(R) - Wed Jun 08, 2:02PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $100.86 to a high of $103.30. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $102.19 on volume of 568,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 101.87 (+0.35)
How Rewarding Investors Believe These Medical Appliances and Equipment Stocks are? - Edwards Lifesciences, Stryker, Accuray, and ABIOMED
PR Newswire - Wed Jun 08, 7:55AM CDT
Increasing demands for new developments are driving up growth in the Medical Appliances and Equipment space, one of the biggest industries in the U.S. Healthcare sector. ActiveWallSt.com has lined the following stocks for investors' assessment: Edwards Lifesciences Corp. (NYSE: EW), Stryker Corp. (NYSE: SYK), Accuray Inc. (NASDAQ: ARAY), and ABIOMED Inc. (NASDAQ: ABMD). Access these stocks complimentary alerts at:
ABMD: 102.54 (+0.01), EW: 101.87 (+0.35), ARAY: 5.29 (-0.01), SYK: 115.00 (+0.44)
Luminex's ARIES Flu A/B & RSV Assay Now CE-IVD Marked
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:04AM CDT
Luminex Corp (LMNX) recently announced the receipt of CE-IVD marking for the ARIES Flu A/B & RSV Assay.
MASI: 51.64 (-0.46), EW: 101.87 (+0.35), LMNX: 20.28 (-0.10), CRY: 11.99 (+0.11)
Look for Shares of Edwards Lifesciences to Potentially Rebound after Yesterday's 1.02% Sell Off
Comtex SmarTrend(R) - Tue May 31, 2:23PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $98.64 to a high of $100.66. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $98.97 on volume of 657,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
EW: 101.87 (+0.35)
Edwards Lifesciences To Present At Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Tue May 31, 1:51PM CDT
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is scheduled to present at the Goldman Sachs 37th Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California on Tuesday, June 7, 2016.
EW: 101.87 (+0.35)
New Strong Buy Stocks for May 27th
Swarup Gupta - ZACKS - Fri May 27, 8:14AM CDT
New Strong Buy Stocks for May 27th
AMAT: 24.00 (-0.07), RESI: 9.42 (-0.04), EW: 101.87 (+0.35), KT: 13.79 (-0.11), TAST: 12.20 (-0.09)
Edwards Lifesciences: Q1 Strong, TAVR Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:50AM CDT
Edwards Lifesciences (EW) made a strong start to 2016, with its first-quarter results beating estimates on both the fronts.
BSX: 22.99 (-0.03), SRDX: 23.63 (+0.44), BAX: 44.50 (+0.01), EW: 101.87 (+0.35)
S&P 500 to Celebrate One Year of New High: Top ETFs & Stocks
Sweta Killa - Zacks Investment Research - Fri May 20, 10:27AM CDT
We have highlighted five ETFs and stocks that have generated incredible returns over the past one-year period and have easily crushed the broader market.
REZ: 64.27 (+0.40), FB: 114.31 (-2.31), KBWP: 49.25 (+0.04), EW: 101.87 (+0.35), CPB: 62.11 (-0.59), TSN: 59.71 (-0.86), RHS: 124.40 (-0.65), PEY: 15.25 (+0.01), CVC: 34.76 (+0.08), PSCU: 47.17 (+0.09)
Baxter (BAX) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:22AM CDT
On May 20, Zacks Investment Research raised Baxter International Inc. (BAX) to a Zacks Rank #1 (Strong Buy).
SRDX: 23.63 (+0.44), MASI: 51.64 (-0.46), BAX: 44.50 (+0.01), EW: 101.87 (+0.35)
Quality Systems (QSII) Q4 Earnings Disappoint, Stock Falls
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:21AM CDT
Shares of Quality Systems Inc. (QSII) plunged almost 10% in after-hours trading following the company's disappointing fourth-quarter fiscal 2016 results.
SRDX: 23.63 (+0.44), MASI: 51.64 (-0.46), EW: 101.87 (+0.35), QSII: 12.41 (-0.03)
Jury Finds in Favor of CardiAQ in Case with Neovasc
PR Newswire - Thu May 19, 2:34PM CDT
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that a federal jury in Boston today returned a verdict in favor of CardiAQ in a lawsuit filed against a former service provider, Neovasc. The jury found that Neovasc breached the non-disclosure agreement between the parties, misappropriated CardiAQ's trade secrets, and breached its duty of honest performance to CardiAQ. The jury also awarded damages of $70 million for trade secret misappropriation.
EW: 101.87 (+0.35)
Masimo (MASI) Scales a 52-Week High on Strong Q1 Results
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:16AM CDT
Shares of Masimo Corp (MASI) scaled a new 52-week high of $48.87 on May 18, eventually closing a tad bit lower at $48.51.
SRDX: 23.63 (+0.44), IRMD: 20.63 (-0.72), MASI: 51.64 (-0.46), EW: 101.87 (+0.35)
Strong Q4 for PetMed (PETS), New Order & Reorder Sales Gain
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:19AM CDT
On May 13, 2016, we issued an updated research report on PetMed Express (PETS).
SRDX: 23.63 (+0.44), MASI: 51.64 (-0.46), PETS: 18.47 (-0.33), EW: 101.87 (+0.35)
Edwards Lifesciences Presents Positive Data on Sapien3
Zacks Equity Research - Zacks Investment Research - Wed May 18, 7:20AM CDT
Results from this study demonstrated a survival rate of 98.1% at the end of 30 days, for patients implanted with a Sapien 3 valve from Edwards Lifesciences (EW).
BSX: 22.99 (-0.03), SRDX: 23.63 (+0.44), BAX: 44.50 (+0.01), EW: 101.87 (+0.35)
Thermo Fisher Posts Solid Q1; Affimetrix Integration Continues
Zacks Equity Research - Zacks Investment Research - Wed May 18, 6:40AM CDT
On May 18, 2016, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO).
IRMD: 20.63 (-0.72), MASI: 51.64 (-0.46), TMO: 151.64 (-0.16), EW: 101.87 (+0.35)
Edwards' Surgical Heart Valve Innovations Demonstrate Positive Patient Benefits
PR Newswire - Tue May 17, 11:57AM CDT
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced positive clinical trial results on two of its advanced innovations in surgical heart valves for the treatment of people with aortic valve disease. Data from three studies--COMMENCE, TRANSFORM and FOUNDATION--were presented as part of the late-breaking sessions at the American Association for Thoracic Surgery's (AATS) 96th annual meeting.
EW: 101.87 (+0.35)
Edwards SAPIEN 3 Transcatheter Valve Demonstrates Positive Patient Outcomes At 30 Days In European Real-World Experience
PR Newswire - Tue May 17, 8:30AM CDT
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that 30-day data from its European post-approval study of the Edwards SAPIEN 3 transcatheter aortic heart valve demonstrated positive patient outcomes, including the lowest reported mortality and stroke rates seen in the SOURCE family of registries.
EW: 101.87 (+0.35)
SmarTrend Watching for Potential Pullback in Shares of Edwards Lifesciences After 1.53% Gain
Comtex SmarTrend(R) - Wed Jun 08, 2:02PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $100.86 to a high of $103.30. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $102.19 on volume of 568,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 101.87 (+0.35)
How Rewarding Investors Believe These Medical Appliances and Equipment Stocks are? - Edwards Lifesciences, Stryker, Accuray, and ABIOMED
PR Newswire - Wed Jun 08, 7:55AM CDT
Increasing demands for new developments are driving up growth in the Medical Appliances and Equipment space, one of the biggest industries in the U.S. Healthcare sector. ActiveWallSt.com has lined the following stocks for investors' assessment: Edwards Lifesciences Corp. (NYSE: EW), Stryker Corp. (NYSE: SYK), Accuray Inc. (NASDAQ: ARAY), and ABIOMED Inc. (NASDAQ: ABMD). Access these stocks complimentary alerts at:
ABMD: 102.54 (+0.01), EW: 101.87 (+0.35), ARAY: 5.29 (-0.01), SYK: 115.00 (+0.44)
Luminex's ARIES Flu A/B & RSV Assay Now CE-IVD Marked
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:04AM CDT
Luminex Corp (LMNX) recently announced the receipt of CE-IVD marking for the ARIES Flu A/B & RSV Assay.
MASI: 51.64 (-0.46), EW: 101.87 (+0.35), LMNX: 20.28 (-0.10), CRY: 11.99 (+0.11)
Look for Shares of Edwards Lifesciences to Potentially Rebound after Yesterday's 1.02% Sell Off
Comtex SmarTrend(R) - Tue May 31, 2:23PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $98.64 to a high of $100.66. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $98.97 on volume of 657,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
EW: 101.87 (+0.35)
Edwards Lifesciences To Present At Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Tue May 31, 1:51PM CDT
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is scheduled to present at the Goldman Sachs 37th Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California on Tuesday, June 7, 2016.
EW: 101.87 (+0.35)
New Strong Buy Stocks for May 27th
Swarup Gupta - ZACKS - Fri May 27, 8:14AM CDT
New Strong Buy Stocks for May 27th
AMAT: 24.00 (-0.07), RESI: 9.42 (-0.04), EW: 101.87 (+0.35), KT: 13.79 (-0.11), TAST: 12.20 (-0.09)
Edwards Lifesciences: Q1 Strong, TAVR Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:50AM CDT
Edwards Lifesciences (EW) made a strong start to 2016, with its first-quarter results beating estimates on both the fronts.
BSX: 22.99 (-0.03), SRDX: 23.63 (+0.44), BAX: 44.50 (+0.01), EW: 101.87 (+0.35)
S&P 500 to Celebrate One Year of New High: Top ETFs & Stocks
Sweta Killa - Zacks Investment Research - Fri May 20, 10:27AM CDT
We have highlighted five ETFs and stocks that have generated incredible returns over the past one-year period and have easily crushed the broader market.
REZ: 64.27 (+0.40), FB: 114.31 (-2.31), KBWP: 49.25 (+0.04), EW: 101.87 (+0.35), CPB: 62.11 (-0.59), TSN: 59.71 (-0.86), RHS: 124.40 (-0.65), PEY: 15.25 (+0.01), CVC: 34.76 (+0.08), PSCU: 47.17 (+0.09)
Baxter (BAX) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:22AM CDT
On May 20, Zacks Investment Research raised Baxter International Inc. (BAX) to a Zacks Rank #1 (Strong Buy).
SRDX: 23.63 (+0.44), MASI: 51.64 (-0.46), BAX: 44.50 (+0.01), EW: 101.87 (+0.35)
Quality Systems (QSII) Q4 Earnings Disappoint, Stock Falls
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:21AM CDT
Shares of Quality Systems Inc. (QSII) plunged almost 10% in after-hours trading following the company's disappointing fourth-quarter fiscal 2016 results.
SRDX: 23.63 (+0.44), MASI: 51.64 (-0.46), EW: 101.87 (+0.35), QSII: 12.41 (-0.03)
Jury Finds in Favor of CardiAQ in Case with Neovasc
PR Newswire - Thu May 19, 2:34PM CDT
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that a federal jury in Boston today returned a verdict in favor of CardiAQ in a lawsuit filed against a former service provider, Neovasc. The jury found that Neovasc breached the non-disclosure agreement between the parties, misappropriated CardiAQ's trade secrets, and breached its duty of honest performance to CardiAQ. The jury also awarded damages of $70 million for trade secret misappropriation.
EW: 101.87 (+0.35)
Masimo (MASI) Scales a 52-Week High on Strong Q1 Results
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:16AM CDT
Shares of Masimo Corp (MASI) scaled a new 52-week high of $48.87 on May 18, eventually closing a tad bit lower at $48.51.
SRDX: 23.63 (+0.44), IRMD: 20.63 (-0.72), MASI: 51.64 (-0.46), EW: 101.87 (+0.35)
Strong Q4 for PetMed (PETS), New Order & Reorder Sales Gain
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:19AM CDT
On May 13, 2016, we issued an updated research report on PetMed Express (PETS).
SRDX: 23.63 (+0.44), MASI: 51.64 (-0.46), PETS: 18.47 (-0.33), EW: 101.87 (+0.35)
Edwards Lifesciences Presents Positive Data on Sapien3
Zacks Equity Research - Zacks Investment Research - Wed May 18, 7:20AM CDT
Results from this study demonstrated a survival rate of 98.1% at the end of 30 days, for patients implanted with a Sapien 3 valve from Edwards Lifesciences (EW).
BSX: 22.99 (-0.03), SRDX: 23.63 (+0.44), BAX: 44.50 (+0.01), EW: 101.87 (+0.35)
Thermo Fisher Posts Solid Q1; Affimetrix Integration Continues
Zacks Equity Research - Zacks Investment Research - Wed May 18, 6:40AM CDT
On May 18, 2016, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO).
IRMD: 20.63 (-0.72), MASI: 51.64 (-0.46), TMO: 151.64 (-0.16), EW: 101.87 (+0.35)
Edwards' Surgical Heart Valve Innovations Demonstrate Positive Patient Benefits
PR Newswire - Tue May 17, 11:57AM CDT
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced positive clinical trial results on two of its advanced innovations in surgical heart valves for the treatment of people with aortic valve disease. Data from three studies--COMMENCE, TRANSFORM and FOUNDATION--were presented as part of the late-breaking sessions at the American Association for Thoracic Surgery's (AATS) 96th annual meeting.
EW: 101.87 (+0.35)
Edwards SAPIEN 3 Transcatheter Valve Demonstrates Positive Patient Outcomes At 30 Days In European Real-World Experience
PR Newswire - Tue May 17, 8:30AM CDT
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that 30-day data from its European post-approval study of the Edwards SAPIEN 3 transcatheter aortic heart valve demonstrated positive patient outcomes, including the lowest reported mortality and stroke rates seen in the SOURCE family of registries.
EW: 101.87 (+0.35)
